LONDON (Alliance News) - Silence Therapeutics PLC Tuesday said pre-clinical study data on the use of its Atu111 RNAi in sepsis was published in the Critical Care Medicine journal.
The study found treatment with Atu111 lung endothelium-targeted RNAi using Silence's DACC delivery system helped ease the severity of sepsis, a whole-of-body inflammation caused by severe infection, and improved survival, both as pre-treatment and as a rescue intervention.
"We were encouraged by the results of our study, which showed that an RNAi therapeutic approach targeting gene expression in the pulmonary endothelium could be a clinically relevant strategy to improve outcomes in septic subjects," said Sascha David of Hannover Medical School, who led the study.
Silence Therapeutics shares were up 2.8% to 213.30 pence on Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
